X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs FDC LTD. - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA FDC LTD. GSK PHARMA/
FDC LTD.
 
P/E (TTM) x 64.9 24.0 270.8% View Chart
P/BV x 10.4 5.0 208.7% View Chart
Dividend Yield % 1.2 0.9 128.2%  

Financials

 GSK PHARMA   FDC LTD.
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
FDC LTD.
Mar-14
GSK PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs3,838144 2,674.6%   
Low Rs2,63779 3,338.0%   
Sales per share (Unadj.) Rs354.247.6 744.6%  
Earnings per share (Unadj.) Rs39.87.6 522.6%  
Cash flow per share (Unadj.) Rs42.99.0 475.8%  
Dividends per share (Unadj.) Rs30.002.25 1,333.3%  
Dividend yield (eoy) %0.92.0 45.8%  
Book value per share (Unadj.) Rs236.947.5 498.5%  
Shares outstanding (eoy) m84.70177.83 47.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x9.12.3 390.8%   
Avg P/E ratio x81.414.6 556.9%  
P/CF ratio (eoy) x75.512.3 611.6%  
Price / Book Value ratio x13.72.3 583.8%  
Dividend payout %75.429.6 255.1%   
Avg Mkt Cap Rs m274,21619,784 1,386.1%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,8301,221 395.7%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,0008,459 354.7%  
Other income Rs m728394 185.0%   
Total revenues Rs m30,7288,852 347.1%   
Gross profit Rs m4,1902,070 202.4%  
Depreciation Rs m263249 105.6%   
Interest Rs m031 0.0%   
Profit before tax Rs m4,6552,184 213.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744606 288.0%   
Profit after tax Rs m3,3681,353 248.9%  
Gross profit margin %14.024.5 57.1%  
Effective tax rate %37.527.7 135.1%   
Net profit margin %11.216.0 70.2%  
BALANCE SHEET DATA
Current assets Rs m16,7424,355 384.4%   
Current liabilities Rs m7,2021,792 401.9%   
Net working cap to sales %31.830.3 104.9%  
Current ratio x2.32.4 95.6%  
Inventory Days Days5244 116.6%  
Debtors Days Days2125 84.2%  
Net fixed assets Rs m8,6353,025 285.5%   
Share capital Rs m847179 474.2%   
"Free" reserves Rs m19,2228,243 233.2%   
Net worth Rs m20,0698,453 237.4%   
Long term debt Rs m1011 93.5%   
Total assets Rs m30,03810,557 284.5%  
Interest coverage xNM71.4-  
Debt to equity ratio x00 39.4%  
Sales to assets ratio x1.00.8 124.6%   
Return on assets %11.213.1 85.5%  
Return on equity %16.816.0 104.8%  
Return on capital %25.523.5 108.3%  
Exports to sales %013.3 0.0%   
Imports to sales %03.3 0.0%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs mNA283 0.0%   
Fx inflow Rs m5281,146 46.1%   
Fx outflow Rs m7,193355 2,024.5%   
Net fx Rs m-6,665791 -842.8%   
CASH FLOW
From Operations Rs m2,3601,485 158.9%  
From Investments Rs m3,008-620 -485.6%  
From Financial Activity Rs m-5,108-753 678.8%  
Net Cashflow Rs m260113 230.8%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.7 217.0%  
FIIs % 23.8 7.5 317.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 19.0 81.1%  
Shareholders   102,036 23,730 430.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  JUBILANT LIFE SCIENCES  STRIDES SHASUN LTD  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 18, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS